Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).
James J. Harding
No relevant relationships to disclose
Federica Catalanotti
No relevant relationships to disclose
Amin Yaqubie
No relevant relationships to disclose
Gregory C. McDermott
No relevant relationships to disclose
Romona Kersellius
No relevant relationships to disclose
Taha Merghoub
No relevant relationships to disclose
Richard D. Carvajal
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Mark Andrew Dickson
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose
Jedd D. Wolchok
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Michael F. Berger
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline; Roche/Genentech
Research Funding - GlaxoSmithKline; Roche/Genentech